Haleos Labs (BOM:540679) LT-Debt-to-Total-Asset: 0.11 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540679 Haleos Labs Ltd BOM:540679
72 GF Score
Price ₹1,600.00
GF Value ₹1,129.65
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Haleos Labs LT-Debt-to-Total-Asset?

Haleos Labs BOM:540679 72 LT-Debt-to-Total-Asset is 0.11 as of Mar. 2026. GuruFocus rates BOM:540679 with a GF Score™ of 72/100 and a GF Value™ of ₹1,129.65 (Significantly Overvalued). The stock has 10 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Haleos Labs's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.11.

Haleos Labs's long-term debt to total assets ratio increased from Mar. 2025 (0.05) to Mar. 2026 (0.11). It may suggest that Haleos Labs is progressively becoming more dependent on debt to grow their business.

Haleos Labs  (BOM:540679) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Haleos Labs LT-Debt-to-Total-Asset Related Terms

Haleos Labs LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Haleos Labs's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haleos Labs LT-Debt-to-Total-Asset Chart

Haleos Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.14 0.09 0.05 0.11

Haleos Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.00 0.04 0.00 0.11
BOM:540679
72GF Score
Haleos Labs Ltd BOM:540679
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haleos Labs LT-Debt-to-Total-Asset Calculation

Haleos Labs's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=507.675/4544.084
=0.11

Haleos Labs's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=507.675/4544.084
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.11 mean?
Haleos Labs (BOM:540679) has a LT-Debt-to-Total-Asset of 0.11 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Haleos Labs and its competitors.
Is Haleos Labs' LT-Debt-to-Total-Asset too high?
Haleos Labs' current LT-Debt-to-Total-Asset is 0.11. Overall, Haleos Labs has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Haleos Labs' LT-Debt-to-Total-Asset of 0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Haleos Labs and its competitors. Haleos Labs's current LT-Debt-to-Total-Asset is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (BOM:540679) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,129.65, compared to a current price of ₹1,600.00 — trading 41.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.11. Haleos Labs' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Haleos Labs (BOM:540679), the current LT-Debt-to-Total-Asset is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haleos Labs (BOM:540679) Overvalued in 2026?

Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued. The current stock price of ₹1,600.00 is trading 41.6% above its estimated GF Value™ of ₹1,129.65. GuruFocus considers Haleos Labs to be Significantly Overvalued.

Key valuation signals for BOM:540679:

  • LT-Debt-to-Total-Asset: 0.11
  • GF Value™: ₹1,129.65 vs. price of ₹1,600.00 (41.6% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the BOM:540679 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haleos Labs Business Description

Other Exchanges HALEOSLABS:India
Address Road Number 71, Plot Number 19 - III, Opposite Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad, TG, IND, 500096
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
72GF Score

Get the complete analysis for BOM:540679

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,600.00
Price
₹1,129.65
GF Value